Compare Stocks: PBLS, BBIO, HALO, and MDGL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BBIO BridgeBio Pharma	$67.13 +3.4%	$73.11	$52.75 ▼ $93.42	$12.69B	0.97	2.97 million shs	2.64 million shs
HALO Halozyme Therapeutics	$121.51 +4.0%	$108.68	$61.22 ▼ $122.33	$13.26B	0.88	2.90 million shs	2.47 million shs
MDGL Madrigal Pharmaceuticals	$459.81 0.0%	$516.27	$393.61 ▼ $615.00	$10.63B	-1.04	278,082 shs	266,163 shs
PBLS Parabilis Medicines	$25.18 -2.7%	$35.44	$24.51 ▼ $42.49	$3.20B	N/A	1.40 million shs	954,611 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BBIO BridgeBio Pharma	+2.59%	-2.35%	-10.28%	-19.13%	+14.94%
HALO Halozyme Therapeutics	+6.57%	+5.44%	+8.23%	+50.66%	+75.27%
MDGL Madrigal Pharmaceuticals	+1.75%	-5.68%	-14.82%	-15.68%	+5.24%
PBLS Parabilis Medicines	-3.58%	-10.17%	-28.40%	-10.91%	+2,588,999,900.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BBIO BridgeBio Pharma	$67.13 +3.4%	$73.11	$52.75 ▼ $93.42	$12.69B	0.97	2.97 million shs	2.64 million shs
HALO Halozyme Therapeutics	$121.51 +4.0%	$108.68	$61.22 ▼ $122.33	$13.26B	0.88	2.90 million shs	2.47 million shs
MDGL Madrigal Pharmaceuticals	$459.81 0.0%	$516.27	$393.61 ▼ $615.00	$10.63B	-1.04	278,082 shs	266,163 shs
PBLS Parabilis Medicines	$25.18 -2.7%	$35.44	$24.51 ▼ $42.49	$3.20B	N/A	1.40 million shs	954,611 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BBIO BridgeBio Pharma	+2.59%	-2.35%	-10.28%	-19.13%	+14.94%
HALO Halozyme Therapeutics	+6.57%	+5.44%	+8.23%	+50.66%	+75.27%
MDGL Madrigal Pharmaceuticals	+1.75%	-5.68%	-14.82%	-15.68%	+5.24%
PBLS Parabilis Medicines	-3.58%	-10.17%	-28.40%	-10.91%	+2,588,999,900.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BBIO BridgeBio Pharma	2.83	Moderate Buy	$104.75	56.04% Upside
HALO Halozyme Therapeutics	2.77	Moderate Buy	$96.50	-20.58% Downside
MDGL Madrigal Pharmaceuticals	2.78	Moderate Buy	$699.20	52.06% Upside
PBLS Parabilis Medicines	2.71	Moderate Buy	$41.67	65.48% Upside

Current Analyst Ratings Breakdown

Latest PBLS, BBIO, HALO, and MDGL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/15/2026	BBIO BridgeBio Pharma	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$82.00 ➝ $92.00
10/14/2026	MDGL Madrigal Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$735.00
10/13/2026	HALO Halozyme Therapeutics	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold ➝ Strong-Buy
10/13/2026	HALO Halozyme Therapeutics	TD Cowen Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$105.00 ➝ $130.00
10/8/2026	HALO Halozyme Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Neutral	$70.00 ➝ $78.00
10/7/2026	HALO Halozyme Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$115.00 ➝ $130.00
10/7/2026	BBIO BridgeBio Pharma	Barclays Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Overweight	$157.00 ➝ $156.00
10/6/2026	BBIO BridgeBio Pharma	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/5/2026	BBIO BridgeBio Pharma	Jefferies Financial Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/5/2026	BBIO BridgeBio Pharma	TD Cowen Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/5/2026	BBIO BridgeBio Pharma	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Overweight

(Data available from 10/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BBIO BridgeBio Pharma	$713.07M	18.40	N/A	N/A	($10.77) per share	-6.23
HALO Halozyme Therapeutics	$1.40B	9.87	$5.29 per share	22.98	$0.42 per share	289.31
MDGL Madrigal Pharmaceuticals	$1.28B	8.27	N/A	N/A	$26.54 per share	17.33
PBLS Parabilis Medicines	$148K	21,017.30	N/A	N/A	N/A	∞

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BBIO BridgeBio Pharma	-$724.93M	-$3.57	N/A	N/A	N/A	-97.03%	N/A	-61.19%	10/28/2026 (Estimated)
HALO Halozyme Therapeutics	$316.89M	$3.35	36.27	12.41	0.41	24.86%	260.98%	23.91%	11/2/2026 (Estimated)
MDGL Madrigal Pharmaceuticals	-$288.28M	-$12.89	N/A	82.85	N/A	-25.32%	-56.65%	-25.53%	11/3/2026 (Estimated)
PBLS Parabilis Medicines	-$145.89M	-$2.13	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest PBLS, BBIO, HALO, and MDGL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/3/2026	Q3 2026	MDGL Madrigal Pharmaceuticals	-$0.8345	N/A	N/A	N/A	$405.27 million	N/A
11/2/2026	Q3 2026	HALO Halozyme Therapeutics	$2.30	N/A	N/A	N/A	$487.13 million	N/A
10/28/2026	Q3 2026	BBIO BridgeBio Pharma	-$0.5633	N/A	N/A	N/A	$281.65 million	N/A
8/13/2026	Q2 2026	PBLS Parabilis Medicines	-$0.16	-$2.32	-$2.16	-$2.32	N/A	$0.15 million
8/10/2026	Q2 2026	BBIO BridgeBio Pharma	-$0.5756	-$0.78	-$0.2044	-$0.78	$220.91 million	$243.68 million
8/6/2026	Q2 2026	HALO Halozyme Therapeutics	$1.79	$2.28	+$0.49	$1.90	$402.28 million	$481.00 million
7/30/2026	Q2 2026	MDGL Madrigal Pharmaceuticals	-$2.68	-$1.99	+$0.69	-$1.99	$352.13 million	$364.25 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BBIO BridgeBio Pharma	N/A	N/A	N/A	N/A	N/A
HALO Halozyme Therapeutics	N/A	N/A	N/A	N/A	N/A
MDGL Madrigal Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PBLS Parabilis Medicines	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BBIO BridgeBio Pharma	N/A	1.23	1.17
HALO Halozyme Therapeutics	13.50	2.71	2.31
MDGL Madrigal Pharmaceuticals	0.65	3.20	2.94
PBLS Parabilis Medicines	N/A	17.91	17.91

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BBIO BridgeBio Pharma	99.85%
HALO Halozyme Therapeutics	97.79%
MDGL Madrigal Pharmaceuticals	98.50%
PBLS Parabilis Medicines	N/A

Insider Ownership

Company	Insider Ownership
BBIO BridgeBio Pharma	14.23%
HALO Halozyme Therapeutics	2.50%
MDGL Madrigal Pharmaceuticals	17.60%
PBLS Parabilis Medicines	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BBIO BridgeBio Pharma	839	195.49 million	167.67 million	Optionable
HALO Halozyme Therapeutics	423	113.50 million	110.66 million	Optionable
MDGL Madrigal Pharmaceuticals	915	23.10 million	19.04 million	Optionable
PBLS Parabilis Medicines	145	123.53 million	N/A	N/A

PBLS, BBIO, HALO, and MDGL Headlines

Recent News About These Companies

Parabilis Medicines, Inc. (PBLS) - What Are Researchers Thinking About This Stock?

October 15 at 2:15 AM | americanbankingnews.com

Parabilis Medicines, Inc. (PBLS) - What Are Analysts Saying About This Stock?

October 15 at 2:13 AM | marketbeat.com

Parabilis Medicines Initiates Dose-Ranging Clinical Cohort Evaluating Zolucatetide in Patients with Familial Adenomatous Polyposis

October 14 at 12:26 AM | marketscreener.comM

Parabilis starts dose-ranging FAP study of zolucatetide

October 14 at 12:26 AM | streetinsider.com

Parabilis Begins Dose-Ranging Study For Zolucatetide In Treating FAP; Data By Q1 '27

October 14 at 12:26 AM | rttnews.com

Parabilis Medicines Advances Zolucatetide Study in Familial Adenomatous Polyposis Patients

October 14 at 12:26 AM | finance.yahoo.com

Parabilis Medicines Initiates Dose-Ranging Clinical Study of Zolucatetide in Familial Adenomatous Polyposis

October 14 at 7:00 AM | globenewswire.com

Parabilis Medicines (NASDAQ:PBLS) Shares Climb 7% - Should You Buy?

October 12 at 12:39 PM | marketbeat.com

Parabilis Medicines (NASDAQ:PBLS) Stock Price Down 7.6% - What's Next?

October 8, 2026 | marketbeat.com

Parabilis Medicines (NASDAQ:PBLS) Shares Down 5.2% - Time to Sell?

October 2, 2026 | marketbeat.com

Parabilis Medicines (NASDAQ:PBLS) Shares Gap Up - Time to Buy?

September 29, 2026 | marketbeat.com

Parabilis Medicines (NASDAQ:PBLS) Shares Up 6% - What's Next?

September 28, 2026 | marketbeat.com

Parabilis Medicines Inc (PBLS)

September 23, 2026 | investing.com

Parabilis Medicines (NASDAQ:PBLS) Stock Price Down 6.3% - What's Next?

September 21, 2026 | marketbeat.com

Parabilis Medicines, Inc. (NASDAQ:PBLS) Given Average Recommendation of "Moderate Buy" by Analysts

September 20, 2026 | marketbeat.com

Why Parabilis Medicines, Inc.’s (PBLS) Stock Is Up 10.09%

September 17, 2026 | aaii.comA

Parabilis Medicines (NASDAQ:PBLS) Hits New 52-Week High - Time to Buy?

September 17, 2026 | marketbeat.com

48,484 Shares in Parabilis Medicines, Inc. $PBLS Acquired by Squarepoint Ops LLC

September 17, 2026 | marketbeat.com

Parabilis Medicines, Inc. (PBLS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 16, 2026 | seekingalpha.com

Parabilis Medicines (NASDAQ:PBLS) Trading Up 6% - Still a Buy?

September 16, 2026 | marketbeat.com

Parabilis Medicines Inc PBLS

September 10, 2026 | morningstar.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

PBLS, BBIO, HALO, and MDGL Company Descriptions

BridgeBio Pharma NASDAQ:BBIO

$67.13 +2.19 (+3.37%)

Closing price 04:00 PM Eastern

Extended Trading

$67.12 -0.01 (-0.01%)

As of 07:52 PM Eastern

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Halozyme Therapeutics NASDAQ:HALO

$121.51 +4.69 (+4.01%)

Closing price 04:00 PM Eastern

Extended Trading

$122.04 +0.52 (+0.43%)

As of 07:49 PM Eastern

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Madrigal Pharmaceuticals NASDAQ:MDGL

$459.81 -0.20 (-0.04%)

Closing price 04:00 PM Eastern

Extended Trading

$459.98 +0.17 (+0.04%)

As of 07:30 PM Eastern

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

Parabilis Medicines NASDAQ:PBLS

$25.18 -0.71 (-2.74%)

As of 04:00 PM Eastern

Parabilis Medicines Inc. is a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease. Parabilis Medicines Inc. is based in CAMBRIDGE, Mass.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PBLS, BBIO, HALO, and MDGL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PBLS, BBIO, HALO, and MDGL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PBLS, BBIO, HALO, and MDGL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PBLS, BBIO, HALO, and MDGL Company Descriptions

BridgeBio Pharma NASDAQ:BBIO

Halozyme Therapeutics NASDAQ:HALO

Madrigal Pharmaceuticals NASDAQ:MDGL

Parabilis Medicines NASDAQ:PBLS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PBLS, BBIO, HALO, and MDGL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PBLS, BBIO, HALO, and MDGL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PBLS, BBIO, HALO, and MDGL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PBLS, BBIO, HALO, and MDGL Company Descriptions

BridgeBio Pharma NASDAQ:BBIO

Halozyme Therapeutics NASDAQ:HALO

Madrigal Pharmaceuticals NASDAQ:MDGL

Parabilis Medicines NASDAQ:PBLS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools